arrow
L

Linda Dirven

leiden university medical center
H指数:41
被引数:7,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-Related Quality of Life in Glioma Subtypes: A Pooled Analysis of 16 Randomized Trials from the CODAGLIO 2.0 project

胶质瘤亚型相关的健康生活质量:CODAGLIO 2.0项目16项随机试验的合并分析

2026-10-010
OAAI
Association between temozolomide-related hematologic toxicity and health-related quality of life (HRQoL) in patients with newly diagnosed glioblastoma

替莫唑胺相关血液学毒性与新诊断胶质母细胞瘤患者健康相关生活质量(HRQoL)的关联

2026-09-080
PRE
International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

国际IV期实地研究以验证欧洲癌症研究与治疗组织问卷用于评估癌症幸存者的健康相关生活质量:EORTC QLQ-SURV100

2026-08-010
PRE
Prognostic value for overall survival of the EORTC QLQ-C30 Summary Score: an analysis of 5 closed EORTC trials

EORTC QLQ-C30总结评分对总生存期的预后价值:对5项已完成的EORTC试验的分析

2026-04-300
OAAI
Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

分子胶质瘤亚型的健康相关生活质量:一项来自16项随机试验的合并分析

2025-11-010
OAAI
The use of EORTC QLQ-C30 Summary Score in cancer research and its performance as compared with the EORTC QLQ-C30 Global Health/Quality of Life scale: A systematic review and comparative analysis of effect sizes

EORTC QLQ-C30总结评分在癌症研究中的应用及其与EORTC QLQ-C30总体健康/生活质量量表性能的比较:一项效应量的系统评价和比较分析

2025-10-260
OAAI
AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE

年龄和性别作为健康相关生活质量结局的危险因素:来自CODAGLIO 2.0数据库临床试验的合并分析

2025-10-010
OAAI
B THE USE OF EORTC QLQ-C30 SUMMARY SCORE IN CANCER CLINICAL TRIALS AND ITS PERFORMANCE AS COMPARED WITH THE GLOBAL HEALTH / QUALITY OF LIFE SCALE: A COMPARATIVE ANALYSIS OF EFFECT SIZES

B 癌症临床试验中EORTC QLQ-C30总结评分的应用及其与全球健康/生活质量量表性能的比较:效应量比较分析

2025-10-010
OA
Challenges in interpreting individual-level changes in health-related quality of life in patients with glioma using minimally important differences (MIDs) and a 4-point Likert scale

使用最小临床重要差异(MIDs)和4点李克特量表解释胶质瘤患者健康相关生命质量个体层面变化所面临的挑战

2025-08-050
OA
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative

基于WHO ICF框架建立神经肿瘤学中使用的患者报告结局指标的内容效度:RANO-PRO计划的一部分

2025-06-010
PRE
Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire
2024-11-011
OAAI
Glioma

胶质瘤

2024-05-0940
PRE